Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Current therapeutic agents: dornase alfa]

D Baran1, J Sternon

  • 1Service de Pneumologie Pédiatrique, Hôpital Erasme, Bruxelles.

Revue Medicale De Bruxelles
|February 1, 1997
PubMed
Summary

Dornase alfa offers a new long-term treatment option for cystic fibrosis patients. This drug addresses clinical, practical, and economic considerations for managing this chronic respiratory condition.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reduced voltage losses yield 10% efficient fullerene free organic solar cells with >1 V open circuit voltages.

Energy & environmental science·2017
Same author

Traitement Des Infections Bronchopulmonaires Aigues Par Le Laurylsulfate De Tetracycline Intra-Musculaire.

Acta clinica Belgica·2016
Same author

Transporting live donor kidneys for kidney paired donation: initial national results.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2011
Same author

Organ donation: a portrait of family refusal in Québec.

Transplantation proceedings·2009
Same author

Lengthy cold ischemia time is a modifiable risk factor associated with low glomerular filtration rates in expanded criteria donor kidney transplant recipients.

Transplantation proceedings·2009
Same author

Recovery of graft function early posttransplant determines long-term graft survival in deceased donor renal transplants.

Transplantation proceedings·2009

Area of Science:

  • Pulmonology
  • Pharmacology
  • Medical Therapeutics

Context:

  • Cystic Fibrosis (CF) is a genetic disorder affecting multiple organs.
  • Pulmonary complications are a major cause of morbidity and mortality in CF.
  • Current CF treatments aim to manage symptoms and improve lung function.

Purpose:

  • To introduce dornase alfa as a novel therapeutic agent for long-term cystic fibrosis management.
  • To evaluate the clinical efficacy, practical administration, and economic viability of dornase alfa.

Summary:

  • Dornase alfa is a recombinant deoxyribonuclease I enzyme.
  • It works by reducing the viscosity of mucus in the airways.
  • Clinical studies demonstrate its benefit in improving lung function and reducing exacerbations in CF patients.

Impact:

  • Dornase alfa represents a significant advancement in cystic fibrosis pharmacotherapy.
  • It offers a new strategy to improve the quality of life for individuals with CF.
  • The economic aspects suggest potential cost-effectiveness in long-term disease management.

Related Experiment Videos